Blue Matter Blog
September 5, 2017
Blue Matter Consulting is tracking oncology market trends on a daily basis, and looks back each month to highlight the newsworthy events shaping our current and future oncology market landscape. Highly Anticipated Approval Granted for Novartis’ CAR-T Therapy The first CAR-T therapy, tisagenlecleucel (Kymriah) has officially been approved for use in heavily pretreated pediatric patients …
August 9, 2017
July Oncology News Roundup: Blue Matter Consulting is tracking oncology market trends on a daily basis, and looks back each month to highlight the newsworthy events shaping our current and future oncology market landscape. Crucial Astra Zeneca IO study fails to show clinical benefit The biggest oncology news of July is also the most recent, …
July 24, 2017
The ODAC hearing on Novartis’ breakthrough CAR-T therapy, tisagenlecleucel, was overwhelmingly positive, as the Committee unanimously recommended approval of the therapy for relapsed or refractory pediatric and young adult patients with b-cell ALL. The hearing paved the way for an efficient regulatory approval of Novartis’ CAR-T therapy, and also provided insight into opportunities for future …
ASCO 2017 met high expectations and delivered a plethora of exciting data. The conference showcased data on promising new molecular targets, combination regimens, and delivery mechanisms in development, and provided valuable insights that will impact current use of commercially available therapies. Blue Matter Consulting is closely tracking the key trends shaping the oncology treatment landscape, …
December 12, 2016
Thirty years after the earliest gene therapies were tested in patients, the promise of this potentially revolutionary class of medicine is now close to fruition. Gene therapy, or the delivery of nucleic acids to cells in order to address diseases linked to genetic mutations, is at the most significant crossroads in its long journey to …
December 9, 2016
The American Society of Hematology, a 58-year-old organization of hematologists, wrapped up its 2016 annual meeting in San Diego this week. The conference features many of the biggest names in the pharmaceutical and biotech industries and serves as a platform to announce new drugs, clinical trial results and initiatives for the future. ASH 2016 was the biggest …
May 1, 2014
Given the average cost and time it takes to successfully bring a drug to market ($1 billion, and 10 years), it’s not surprising that pharmaceutical companies have sought to de-risk their R&D portfolios by acquiring later stage, more clinically-advanced molecules. However, The Accelerating Medicines Partnership (AMP), a collaboration between the NIH and 10 drug companies …